Sonnet Biotherapeutics Holdings

SONN · NASDAQ

$51.02+$51.02 (+0.00%)TodayMarket closed ·
Prev close $0.00

About SONN

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to target tumors and lymphatic tissue. The firm's lead program, SON-1010 (IL-12-FHAB), is a single-chain version of human Interleukin 12 (IL-12), linked to the FHAB construct, for which pursuing clinical development in solid tumor indications, including ovarian cancer, soft tissue sarcoma, colorectal cancer, and breast cancer. Its SON-1210 (IL12-FHAB-IL15), is a bifunctional construct, combines FHAB with single-chain human IL-12 and human Interleukin 15 (IL-15). Its SON-080 is in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Employees
13
Headquarters
Princeton, New Jersey
Listed
Jul 27, 2005
Sector
Health Care
Industry
Biotechnology

SONN key statistics

Market cap
8.92M
Price-earnings ratio
—
Dividend yield
—
Average volume
1.71M
Volume
1.18M
Open price
$51.58
High today
$51.83
Low today
$51.00
52 Week high
$5.95
52 Week low
$1.26

Sonnet Biotherapeutics Holdings (SONN) at a glance

As of Nov 20, 2026, Sonnet Biotherapeutics Holdings (SONN) shares are priced at $51.02, giving the company a market cap of 8.92M.

On Nov 20, 2026, the stock traded between $51.00 and $51.83. Its last price was 0.0% above the day's low and 1.6% below its high.

Volume on Nov 20, 2026 reached 1.18M shares, below the average of 1.71M shares a day.

Over the past year Sonnet Biotherapeutics Holdings has ranged from $1.26 to $5.95, and now sits 1061% of the way up that range.

Sonnet Biotherapeutics Holdings met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY25 it reported -$0.95 per share against an estimate of -$0.4998.

SONN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 32.7% on average.

  1. Q4 FY23: reported -$16.72 per share against an estimate of -$33.40
  2. Q1 FY24: reported -$2.48 per share against an estimate of -$7.34
  3. Q2 FY24: reported $0.56 per share against an estimate of $1.10
  4. Q3 FY24: reported -$5.60 per share against an estimate of -$6.24
  5. Q4 FY24: reported -$3.83 per share against an estimate of -$5.63
  6. Q1 FY25: reported -$1.56 per share against an estimate of -$1.42
  7. Q2 FY25: reported -$0.89 per share against an estimate of -$0.9384
  8. Q3 FY25: reported -$0.95 per share against an estimate of -$0.4998

SONN news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseGlobe Newswire

    Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HBI, BFIN, PBBK, SONN on Behalf of Shareholders

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: SONN, SKX, FCCO, and SGBG

  • Shivdeep Dhaliwal

    Palantir, The Trade Desk, Tilray, Sonnet Biotherapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Similar companies

Companies in the same industry as Sonnet Biotherapeutics Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.